Abstract
Prescription drugs have enormous potential to improve health and longevity, and the past decades have witnessed remarkable innovations in the pharmaceutical marketplace. Despite this, the past decades are also replete with examples of therapies, ranging from thalidomide to rofecoxib to sibutramine, that have raised important safety concerns. The recent outbreak of fungal meningitis linked to unsterile practices at a compounding pharmacy serves as yet another cautionary tale that all drugs have risks and that drugs are manufactured, produced, delivered, and administered in a complex regulatory and clinical environment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
